Schilke Tobin's Form 4 filing
Revance Therapeutics, Inc. (RVNC) · filed Mar 9, 2023
- Accession no.
- 0001479290-23-000036
- Filed
- Mar 9, 2023
- Trade date
- Sep 22, 2022-Mar 9, 2023
- Filing delay
- 168 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $585.0K. It was filed 168 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schilke TobinCIK 0001678984 | Officer (CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2022 | Common Stock | AGrant or awardAcquired | +42,349 | $0.00 | $0 | 91,739 | Direct | |
| Mar 9, 2023 | Common Stock | SSaleDisposed | −18,517 | $31.59 | −$584,952.03 | 73,222 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.